Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

Advancing Affordable, Immune-Based Multi-Cancer Early Detection

Objectif

Cancer is the second leading cause of death in Europe, and its burden is expected to rise sharply, with the World Health Organization projecting a 77% increase in cases by 2050. Despite commitments to expand population-based screening, 50% of cancers are still detected at advanced stages and 70% of cancer deaths arise from cancers without available screening. Current multicancer detection tests, largely based on circulating tumour DNA (ctDNA), remain too insensitive for early-stage disease and too expensive for widespread use (~€875 per patient), making them unsuitable for population-scale implementation.
Enlighten®, developed by Proteotype Diagnostics, introduces a new approach to multicancer early detection (MCED), by measuring the host’s immune-driven proteomic response rather than scarce tumour-derived material. Using a simple fluorescence-based kit and an AI classifier, Enlighten® quantifies Protein Cross Sections directly from neat plasma. Independent validation shows high stage I sensitivity, with 95% overall sensitivity and 100% specificity across multiple solid tumours, at a price point compatible with decentralised, population-level screening.
The Enlighten Pre-Accelerator project will advance Enlighten® from TRL 5 to TRL 6 and BRL 4 to BRL 6 through AI model optimisation, multi-geography data harmonisation, and development of a clinician-ready digital interface. Cloud security, interoperability and SaMD documentation will be strengthened to meet IVDR and ISO 13485/IEC 62304 requirements. These activities will deliver a clinically verified, regulatory-ready platform and establish a clear pathway toward pivotal validation studies and EIC Accelerator funding.
The Enlighten Pre-Accelerator will deliver a CE-ready TRL6/BRL6 platform for affordable MCED. Enlighten® has the potential to become Europe’s first scalable MCED solution, reducing late-stage diagnoses, lowering healthcare expenditure, and enabling more equitable access to cancer prevention.

Champ scientifique (EuroSciVoc)

Ce projet n'a pas encore été classé par EuroSciVoc.
Proposez les domaines scientifiques qui vous semblent les plus pertinents et aidez-nous à améliorer notre service de classification.

Mots‑clés

Programme(s)

Thème(s)

Régime de financement

HORIZON-CSA - HORIZON Coordination and Support Actions

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) HORIZON-WIDERA-2025-02

Voir tous les projets financés au titre de cet appel

Coordinateur

PROTEOTYPE DIAGNOSTICS UNIPESSOAL LDA
Contribution nette de l'UE
€ 498 840,56
Adresse
RUA DR GOMES LEAL N3A
2560-331 TORRES VEDRAS
Portugal
PME
Oui
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Liens
Coût total
Aucune donnée